Friday, 29 March 2024
Aclaris Therapeutics Inc.
-
Overlay
-
Indicators
-
Settings
-
Period
10:30 | 14/3/18
Equities.com
Aclaris Therapeutics Inc. (ACRS) traded on unusually high volume on Mar. 13, as the stock gained 0.56% to close at $19.86. On the day, Aclaris Therapeutics Inc. saw 568,376 shares trade hands on 5,512 trades. Considering that the stock averages only a ...
more»
02:07 | 14/3/18
StockNewsGazette
The shares of Mondelez International, Inc. have increased by more than 3.71% this year alone. The shares recently went up by 0.27% or $0.12 and now trades at $44.39.
more»
04:11 | 13/3/18
Post Analyst
Gilead Sciences, Inc. (NASDAQ:GILD) recent rally took place on significantly less volume which dipped to nearly 7.03 million contracts on 09-Mar-18 versus its daily average of 8.82 million.
more»
01:00 | 13/3/18
Market Exclusive
On March 12, 2018, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2017, as well as information regarding a conference call to discuss these financial ...
more»
23:52 | 12/3/18
GlobeNewswire
WAYNE, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in ...
more»
01:45 | 11/3/18
Frisco Fastball
Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.90 EPS on March, 21.They anticipate $0.41 EPS change or 83.67 % from last quarter's $-0.49 EPS.
more»
01:56 | 10/3/18
GlobeNewswire
WAYNE, Pa., March 09, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address ...
more»
09:41 | 9/3/18
Analyst Journal
Education Realty Trust, Inc. (NYSE:EDR) shares ended at $32.19 with 0.39 mln shares exchanging hands. That puts the market capitalization at $2.44 bln.
more»
06:37 | 9/3/18
Frisco Fastball
Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.90 EPS on March, 21.They anticipate $0.41 EPS change or 83.67 % from last quarter's $-0.49 EPS.
more»
21:48 | 8/3/18
Week Herald
Aclaris Therapeutics logo Aclaris Therapeutics Inc (NASDAQ:ACRS) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports.
more»